n INTRODUCTION R heumatoid arthritis (RA) is a chronic inflammatory and immune-mediated systemic pathological condition with a multifactorial etiology. Progression of joint damage, physical disability and reduced quality of life (QOL) are the essential aspects of this disease (1-5).
In clinical practice, approximately 30% of RA patients interrupt treatment with anti-TNF drugs during the first year due to a lack of efficacy or onset of adverse events (6) (7) (8) (9) . The clinical efficacy of rituximab in terms of response to the American College of Rheumatology (ACR) and of the European League Against Rheumatism (EULAR) criteria was investigated in two controlled, SUMMARY The paper reports the results from the observational retrospective-prospective RUBINO study conducted in Italy to assess the safety of rituximab in the treatment of rheumatoid arthritis (RA) in routine clinical practice. The percentage of patients who manifested at least one grade 3 or 4 adverse event (AE) assessed by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v.3) during the observation period (primary objective) was evaluated. The percentage of patients manifesting a severe AE (SAE), clinical response to rituximab treatment, clinical remission according to disease activity score for 28 joints (DAS28) criteria, markers of disease and quality of life were also assessed. Fifty-three Italian rheumatology centers took part in the study. Patients with a diagnosis of RA and inadequate response to anti-tumor necrosis factor b (anti-TNFa) drugs were enrolled. Participating patients had previously received at least one cycle of rituximab, and treatment was still ongoing at the time of recruitment. Out of 205 patients enrolled, 60% manifested no form of AE, 14.2% had at least one grade 3 or 4 AE, and 11.2% patients reported an SAE. The overall percentage of patients manifesting AEs (40%) was lower compared to the DANCER (81% and 85%), REFLEX (85%) and RESET (85% and 69%) studies, but higher than that observed in the CERERRA registry (from 10.2% to 13.9%). This difference may be due to the shorter observation period applied in the CERERRA registry (only 12 months) compared to the RUBINO study (up to 3 years). All parameters of RA activity (erythrocyte sedimentation rate, C-reactive protein, health assessment questionnaire score, DAS28) improved significantly during the study. 
ORIGINAL ARTICLE
Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy double blind clinical trials (DANCER and REFLEX) with good results. In the DANC-ER study, 73% and 67% of patients receiving 2x1000 mg and 2x500 mg of rituximab respectively achieved a moderate to good response at week 24. In the REFLEX study, a 51% increase in ACR 20 and a 65% response to EULAR were observed (10, 11) . In patients treated with rituximab a significant reduction in disease activity and health assessment questionnaire (HAQ) disability index were observed compared to patients treated with methotrexate single therapy. The studies cited above provide further confirmation of the good safety profile of rituximab. The percentage of patients on rituximab reporting adverse events ranges from 81% to 85%, compared with 70% of patients receiving placebo. The most common adverse events were infusion reactions of mild to moderate intensity, which were more frequent during the first infusion and decreased following administration of glucocorticoids. In the REFLEX study, only 18% of patients treated with rituximab plus methotrexate reported severe grade (3 and 4) adverse events. This percentage does not appear to differ significantly from that reported by patients receiving placebo plus methotrexate. Serious adverse events (SAE) were reported by 7% of patients in the rituximab plus methotrexate group, and by 10% in the placebo plus methotrexate group. The safety profile of rituximab was also investigated in long-term studies showing that the repeated depletion of B lymphocytes is well tolerated over time (12) . One study reported how, in patients failing to respond to TNFa inhibitors, the safety profile remained unchanged after repeated courses of rituximab. Likewise this trend remained constant in patients treated with up to seven cycles at 6-12 month intervals (13, 14) . The economic impact of RA and its consequences on QOL acquire an increasingly important role with worsening of the disease and disease duration (15) . Recent studies have indicated that biological medicines such as rituximab are characterized by more favorable cost/efficacy and cost/ usefulness ratios compared to traditional treatments, thus playing a central role in the treatment of RA (16) (17) (18) (19) (20) . The aim of the RUBINO study was to gather information from routine clinical practice on the use of rituximab and its related clinical impacts, with specific focus on the incidence of adverse events (AE/SAE). The primary endpoint was to evaluate the percentage of patients manifesting at least one grade 3 or 4 adverse event [according to Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v.3)] during the observation period. Furthermore, the study evaluated: the percentage of patients who i) manifested at least one SAE, ii) interrupted rituximab treatment, iii) underwent a second treatment cycle, as well as time to retreatment. Time to response and identification of factors affecting response to rituximab were also assessed. Finally, the study aimed to evaluate clinical remission according to disease activity score (DAS28) criteria, and correlation with patients' QOL during rituximab treatment.
n MATERIALS AND METHODS
An observational, retrospective and prospective multi-center cohort study was carried out. Fifty-three Italian rheumatology centers took part in the study. Eligible subjects were adult male and female patients with a diagnosis of RA according to the ACR 1987 revised criteria (21) , who had displayed inadequate response or intolerance to TNFa inhibitors and had started treatment with rituximab over the 12 months prior to the study and were still on treatment at the time of recruitment. Patients with severe active infections, hypersensitivity to the active component or to murine proteins of rituximab, degree IV congestive heart failure, pregnancy or concomitant participation in other clinical trials were not treated with rituximab. All eligible patients gave their written informed consent to take part in the study. As this was an observational trial, standard treatments were prescribed and no additional diagnostic or monitoring procedures were applied. Subjects were followed pro- n RESULTS
Study population
Two hundred and five RA patients meeting the inclusion/exclusion criteria were enrolled in the study. Mean duration of the disease (SD) was 14 years (7.2) and 80.5% of enrolled patients (N=165) were females. (Fig. 1) . QOL was assessed by means of HAQ at 6, 12 and 24 months in both patients in clinical remission and unremitted patients. Mean HAQ score was lower in patients in clinical remission than for those who were not in remission at each visit. After 6 months, a mean (SD) score of 0.63 (0.67) in patients in clinical remission, and 1.37 (0.83) in those not in remission was seen (P<0.0002). After one year, a score of 0.61 (0.47) was obtained for patients in remission, and 1.48 (0.79) for unremitted patients (P<0.0001). After 24 months, subjects in remission displayed a mean (SD) HAQ score of 0.68 (0.68), while those not During the observation period, 67% of patients (N=137) were not admitted to hospital, 8.8% (N=18) were hospitalized once and 11.2% (N=23) were hospitalized twice. Over the same period 87.3% of patients (N=179) made no visits to an emergency department, while 23 patients (11.2%) visited it once, and 3 (1.5%) twice. Out of 205 enrolled patients, 128 (62.44%) did not visit their general practitioner during the observation period, while 14 (6.83%) did it approximately once/year.
n DISCUSSION
The aim of this observational study was to assess the safety of rituximab over a period of observation lasting up to 3.4 years. Out of 205 patients enrolled in the study, 123 (60%) failed to report the onset of any AEs, 53 (25.9%) reported AEs of grade 1 or 2, while 29 (14.2%) manifested at least one grade 3 or 4 AE. Overall, AEs were reported by 82 patients (40%), a much lower percentage than that reported in the DANCER, REFLEX and RESET studies (85% in all three studies after the first treatment cycle) (10, 11, 26) . However, the 40% observed in this study is higher than that reported in the CERERRA registry (from 13.9% in patients on rituximab monotherapy to 10.2% in patients receiving rituximab plus leflunomide) (27). This difference could be explained by the fact that patients from the CERERRA study were observed over a 12-month period, while the RUBINO study collected safety information for up to 3 years. On the contrary, the percentage of patients manifesting SAEs was higher in the RU-BINO (11.22%) than in the DANCER and REFLEX studies. In the DANCER study, 7% of patients with SAEs were observed in the 2x500 mg rituximab group, while 2% of serious infectious events and 5% of non-infectious SAEs were observed in the 2x1000 mg rituximab group. In the REFLEX study, 7% of patients receiving rituximab plus methotrexate manifested SAEs. This difference could be explained by the comorbidity profile of enrolled patients and by the longer observation period of the RUBINO study compared to the other studies (up to 3.4 years vs 24 weeks in DANCER and REFLEX studies). In the RUBINO study, the majority of AEs (55.6%) were mild (grade 1) and in 42.8% of cases AEs were deemed unrelated to the administration of any drug, as suggested also by the type of events manifested. Twenty-three percent of AEs were represented by infusion-related reactions, although definitive discontinuation of rituximab administration was required only in a few cases (6.4%). The changes in parameters and markers of RA during the observation period are of particular interest. Changes in DAS28 score appear to be related to initial DAS28 values. The DAS28 median score was 5.1 at baseline and subsequently showed a statistically significant decrease to 3.3 after 6 months, to 3.4 after 12 months and 3.1 after 24 months, indicating a satisfactory maintenance of the effect. Fifty percent of response to treatment was observed within 7 months. Over the 24-month study period, median ESR and CRP showed a significant decrease versus baseline. They dropped from 41 to 16, and from 1.7 to 0.6 respectively and, as expected, mean HAQ score was significantly lower in patients in clinical remission after 6, 12 and 24 months of observation. Based on the data available, gender and concomitant diseases did not appear to influence the response to rituximab. This study was conceived in 2008, when the relationship between serological status and response to rituximab was still not fully understood. Indeed, this trial led to the observation that, in clinical practice, the choice of rituximab was based on the severity of the illness rather than on the serological status, and that rituximab was prescribed irrespective of the presence of concomitant diseases. It is moreover noteworthy that no association was found between the rituximab treatment and the increased use of healthcare resources, as observed from the reduced number of visits to the GP and number of 
